[1] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1):7-30. [2] ABUBAKAR M, FIGUEROA J, ALI H R, et al. Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer[J]. Mod Pathol, 2019, 32(9):1244-1256. [3] ROSINSKI J A, ATCHLEY W R. Molecular evolution of the Myb family of transcription factors:evidence for polyphyletic origin[J]. J Mol Evol, 1998, 46(1):74-83. [4] MITRA P. Transcription regulation of MYB:a potential and novel therapeutic target in cancer[J]. Ann Transl Med, 2018, 6(22):443. [5] MUSA J, AYNAUD M M, MIRABEAU O, et al. MYBL2(B-Myb):a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis[J]. Cell Death Dis, 2017, 8(6):e2895. [6] YANG R, NANAYAKKARA D, KALIMUTHO M, et al. MYB regulates the DNA damage response and components of the homology-directed repair pathway in human estrogen receptor-positive breast cancer cells[J]. Oncogene, 2019, 38(26):5239-5249. [7] KIM J, GEYER F C, MARTELOTTO L G, et al. MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene[J]. J Pathol, 2018, 244(2):143-150. [8] ANDREASEN S, TAN Q, AGANDER T K, et al. Adenoid cystic carcinomas of the salivary gland, lacrimal gland, and breast are morphologically and genetically similar but have distinct microRNA expression profiles[J]. Mod Pathol, 2018, 31(8):1211-1225. [9] QU X, YAN X, KONG C, et al. C-Myb promotes growth and metastasis of colorectal cancer through c-fos-induced epithelial-mesenchymal transition[J]. Cancer Sci, 2019, 110(10):3183-3196. [10] WANG X, ANGELIS N, THEIN S L. MYB-A regulatory factor in hematopoiesis[J]. Gene, 2018, 665:6-17. [11] RAMKISSOON L A, HOROWITZ P M, CRAIG J M, et al. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1[J]. Proc Natl Acad Sci USA, 2013, 110(20):8188-8193. [12] GOLAY J, LUPPI M, SONGIA S, et al. Expression of A-myb, but not c-myb and B-myb, is restricted to Burkitt's lymphoma, sIg+ B-acute lymphoblastic leukemia, and a subset of chronic lymphocytic leukemias[J]. Blood, 1996, 87(5):1900-1911. [13] DEDIĆ PLAVETIĆ N, JAKIĆ-RAZUMOVIĆ J, KULIĆ A, et al. Prognostic value of proliferation markers expression in breast cancer[J]. Med Oncol, 2013, 30(2):523. [14] XIONG Y C, WANG J, CHENG Y, et al. Overexpression of MYBL2 promotes proliferation and migration of non-small-cell lung cancer via upregulating NCAPH[J]. Mol Cell Biochem, 2020, 468(1/2):185-193. [15] GUAN Z, CHENG W, HUANG D, et al. High MYBL2 expression and transcription regulatory activity is associated with poor overall survival in patients with hepatocellular carcinoma[J]. Curr Res Transl Med, 2018, 66(1):27-32. [16] RHODES D R, YU J, SHANKER K, et al. ONCOMINE:a cancer microarray database and integrated data-mining platform[J]. Neoplasia, 2004, 6(1):1-6. [17] TANG Z F, KANG B X, LI C W, et al. GEPIA2:an enhanced web server for large-scale expression profiling and interactive analysis[J]. Nucleic Acids Res, 2019, 47(W1):W556-W560. [18] The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours[J]. Nature, 2012, 490(7418):61-70. [19] GAO J, AKSOY B A, DOGRUSOZ U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal[J]. Sci Signal, 2013, 6(269):pl1. [20] JÉZÉQUEL P, CAMPONE M, GOURAUD W, et al. Bc-GenExMiner:an easy-to-use online platform for gene prognostic analyses in breast cancer[J]. Breast Cancer Res Treat, 2012, 131(3):765-775. [21] JÉZÉQUEL P, FRÉNEL J S, CAMPION L, et al. Bc-GenExMiner 3.0:new mining module computes breast cancer gene expression correlation analyses[J]. Database (Oxford), 2013, 2013:bas060. [22] GYÖRFFY B, LANCZKY A, EKLUND A C, et al. An online survival analysis tool to rapidly assess the effect of 22, 277 genes on breast cancer prognosis using microarray data of 1, 809 patients[J]. Breast Cancer Res Treat, 2010, 123(3):725-731. [23] LI Q, BIRKBAK N J, GYORFFY B, et al. Jetset:selecting the optimal microarray probe set to represent a gene[J]. BMC Bioinformatics, 2011, 12:474. [24] DENNIS G, SHERMAN B T, HOSACK D A, et al. DAVID:database for annotation, visualization, and integrated discovery[J]. Genome Biol, 2003, 4(5):P3. [25] CURTIS C, SHAH S P, CHIN S F, et al. The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups[J]. Nature, 2012, 486(7403):346-352. [26] GLÜCK S, ROSS J S, ROYCE M, et al. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ±trastuzumab[J]. Breast Cancer Res Treat, 2012, 132(3):781-791. [27] SORLIE T, TIBSHIRANI R, PARKER J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets[J]. Proc Natl Acad Sci USA, 2003, 100(14):8418-8423. [28] LIU X, XU Y, HAN L, et al. Reassessing the potential of myb-targeted anti-cancer therapy[J]. J Cancer, 2018, 9(7):1259-1266. [29] MITRA P, PEREIRA L A, DRABSCH Y, et al. Estrogen receptor-α recruits P-TEFb to overcome transcriptional pausing in intron 1 of the MYB gene[J]. Nucleic Acids Res, 2012, 40(13):5988-6000. [30] DRABSCH Y, HUGO H, ZHANG R, et al. Mechanism of and requirement for estrogen-regulated MYB expression in estrogen-receptor-positive breast cancer cells[J]. Proc Natl Acad Sci USA, 2007, 104(34):13762-13767. [31] AHN S G, CHA Y J, BAE S J, et al. Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer[J]. BMC Cancer, 2018, 18(1):320. [32] PFISTER K, PIPKA J L, CHIANG C, et al. Identification of drivers of aneuploidy in breast tumors[J]. Cell Rep, 2018, 23(9):2758-2769. [33] INESS A N, FELTHOUSEN J, ANANTHAPADMANABHAN V, et al. The cell cycle regulatory DREAM complex is disrupted by high expression of oncogenic B-Myb[J]. Oncogene, 2019, 38(7):1080-1092. [34] UXA S, BERNHART S H, MAGES C F S, et al. DREAM and RB cooperate to induce gene repression and cell-cycle arrest in response to p53 activation[J]. Nucleic Acids Res, 2019, 47(17):9087-9103. [35] MALMGREN J A, MAYER M, ATWOOD M K, et al. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time:1990-2010[J]. Breast Cancer Res Treat, 2018, 167(2):579-590. [36] TAO D, PAN Y, JIANG G, et al. B-Myb regulates snail expression to promote epithelial-to-mesenchymal transition and invasion of breast cancer cell[J]. Med Oncol, 2015, 32(1):412. [37] WOLTER P, HANSELMANN S, PATTSCHULL G, et al. Central spindle proteins and mitotic kinesins are direct transcriptional targets of MuvB, B-MYB and FOXM1 in breast cancer cell lines and are potential targets for therapy[J]. Oncotarget, 2017, 8(7):11160-11172. |